EGFR and head and neck squamous cell carcinoma: Among ADCs, MRG003 (anti-EGFR-MMAE) has reported ORR 43% with mOS 11.3 mo in heavily pretreated EGFR-positive HNSCC and is in Phase III against investigator’s choice, underscoring class potency with acceptable tolerability for refractory patients [115,116].